Sponsor Pipeline

Cogent Biosciences, Inc. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
4
Recruiting
1
Phase 3
7
Disease Areas
Active Trials by Phase
Phase 3
1
Phase 2
2
Phase 1/2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05208047 (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With… Advanced Gastrointestinal Stromal Tumors Recruiting
Phase 2
NCT04996875 (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis Advanced Systemic Mastocytosis (AdvSM) Recruiting
NCT05186753 (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in… SSM Active, Not Recruiting
Phase 1/2
NCT06777316 A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other… Intrahepatic Cholangiocarcinoma (Icc) Active, Not Recruiting
Phase 1
NCT07361562 A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors Advanced Solid Tumor, Adult Recruiting
NCT07383506 A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors PIK3CA Mutations Recruiting
Disease Areas
Breast Cancer (2) Leukemia (1) Mantle Cell Lymphoma (1) Cholangiocarcinoma (1) Non-Small Cell Lung Cancer (NSCLC) (1) Lung Cancer (1) Endometrial Cancer (1)
Get alerts when Cogent Biosciences, Inc.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free